Published in Science on March 20, 2009
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol (2010) 3.70
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol (2013) 1.71
Nature-inspired design of motif-specific antibody scaffolds. Nat Biotechnol (2013) 1.68
Computationally Designed Bispecific Antibodies using Negative State Repertoires. Structure (2016) 1.45
Computer-aided antibody design. Protein Eng Des Sel (2012) 1.44
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell (2014) 1.31
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs (2012) 1.29
CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol (2012) 1.27
Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol (2012) 1.26
Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A (2011) 1.26
Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A (2010) 1.24
Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A (2010) 1.24
General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A (2012) 1.17
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker. PLoS One (2012) 1.13
A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches. Protein Sci (2011) 1.12
Biosimilar, biobetter and next generation therapeutic antibodies. MAbs (2011) 1.05
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One (2011) 1.03
Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs (2015) 1.02
World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. MAbs (2012) 1.02
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs (2011) 1.02
Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther (2010) 0.98
Reconciling views on T cell receptor germline bias for MHC. Trends Immunol (2012) 0.98
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem (2010) 0.97
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem (2015) 0.95
The human IgE repertoire. Int Arch Allergy Immunol (2013) 0.94
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc Natl Acad Sci U S A (2012) 0.94
Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun (2015) 0.93
Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs (2013) 0.93
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs (2011) 0.92
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol (2016) 0.91
Investigating endogenous peptides and peptidases using peptidomics. Biochemistry (2011) 0.91
Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs (2011) 0.90
Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS One (2011) 0.89
A genetically encoded aza-Michael acceptor for covalent cross-linking of protein-receptor complexes. J Am Chem Soc (2014) 0.88
LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J Biol Chem (2012) 0.88
Origins of specificity and affinity in antibody-protein interactions. Proc Natl Acad Sci U S A (2014) 0.87
5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland. MAbs (2011) 0.87
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat (2011) 0.86
Back to the future: recombinant polyclonal antibody therapeutics. Curr Opin Chem Eng (2013) 0.86
Synthetic Fab fragments that bind the HIV-1 gp41 heptad repeat regions. Biochem Biophys Res Commun (2011) 0.86
Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. Elife (2013) 0.85
Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics. Bioorg Med Chem Lett (2009) 0.85
Structural model for the interaction of a designed Ankyrin Repeat Protein with the human epidermal growth factor receptor 2. PLoS One (2013) 0.85
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release (2012) 0.85
Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG. J Virol (2013) 0.85
Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment. Nucleic Acids Res (2015) 0.85
Recent advances in the field of anti-cancer immunotherapy. BBA Clin (2015) 0.85
Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell (2010) 0.84
The making of bispecific antibodies. MAbs (2017) 0.84
Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. PLoS One (2013) 0.83
In vitro Fab display: a cell-free system for IgG discovery. Protein Eng Des Sel (2014) 0.82
Genetic elimination of α3(IV) collagen fails to rescue anti-collagen B cells. Immunol Lett (2011) 0.82
The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs (2016) 0.82
In situ click chemistry: from small molecule discovery to synthetic antibodies. Integr Biol (Camb) (2013) 0.81
Quantitative specificity-based display library screening identifies determinants of antibody-epitope binding specificity. Protein Sci (2009) 0.81
Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies. Proc Natl Acad Sci U S A (2015) 0.80
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan. MAbs (2011) 0.80
Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother (2016) 0.80
Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front Immunol (2016) 0.80
Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display. Virology (2015) 0.79
In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin. Adv Biomed Res (2012) 0.79
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration. Proc Natl Acad Sci U S A (2015) 0.79
High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface. MAbs (2014) 0.78
Antigen clasping by two antigen-binding sites of an exceptionally specific antibody for histone methylation. Proc Natl Acad Sci U S A (2016) 0.78
A phosphorylation pattern-recognizing antibody specifically reacts to RNA polymerase II bound to exons. Exp Mol Med (2016) 0.78
Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions. J Biol Chem (2012) 0.78
Identification and characterization of a multispecific monoclonal antibody G2 against chicken prion protein. Protein Sci (2014) 0.77
Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypes. BMC Genomics (2015) 0.77
A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions. MAbs (2014) 0.77
Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration. J Biol Chem (2015) 0.77
An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo. MAbs (2014) 0.77
Immunology. Two-in-one designer antibodies. Science (2009) 0.77
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs (2016) 0.77
Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry. J Biol Chem (2011) 0.77
Nucleotide insertions and deletions complement point mutations to massively expand the diversity created by somatic hypermutation of antibodies. J Biol Chem (2014) 0.76
Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor. MAbs (2014) 0.76
Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs (2016) 0.76
Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain. MAbs (2017) 0.75
Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. MAbs (2016) 0.75
Tetraspecific ligand for tumor-targeted delivery of nanomaterials. Biomaterials (2014) 0.75
HIV: Antibodies with a split personality. Nature (2010) 0.75
Antigenic Determinants of Der p 1: Specificity and Cross-Reactivity Associated with IgE Antibody Recognition. J Immunol (2016) 0.75
Directed Evolution of a Highly Specific FN3 Monobody to the SH3 Domain of Human Lyn Tyrosine Kinase. PLoS One (2016) 0.75
Iterative non-proteinogenic residue incorporation yields α/β-peptides with a helix-loop-helix tertiary structure and high affinity for VEGF. Chembiochem (2016) 0.75
Designing two-in-one antibodies. Immunotherapy (2009) 0.75
A multispecific monoclonal antibody G2 recognizes at least three completely different epitope sequences with high affinity. Protein Sci (2017) 0.75
Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions. Protein Sci (2017) 0.75
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Mol Ther (2017) 0.75
Assisted Design of Antibody and Protein Therapeutics (ADAPT). PLoS One (2017) 0.75
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab (2007) 5.04
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
A specificity map for the PDZ domain family. PLoS Biol (2008) 3.16
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis (2003) 2.90
High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol (2007) 2.88
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A (2004) 2.17
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol (2004) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 2.03
Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J (2004) 1.94
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci U S A (2003) 1.78
Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A (2004) 1.75
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A (2007) 1.73
Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem (2007) 1.73
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem (2005) 1.69
Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol (2006) 1.68
In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics (2002) 1.66
Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nat Chem Biol (2009) 1.65
Macrophage complement receptors and pathogen clearance. Cell Microbiol (2007) 1.65
Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci (2008) 1.63
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res (2006) 1.61
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res (2007) 1.59
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
PET of glial metabolism using 2-18F-fluoroacetate. J Nucl Med (2009) 1.56
Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol (2004) 1.53
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52
Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families. J Biol Chem (2006) 1.49
Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J (2007) 1.43
The crystal structure of murine coronin-1: a regulator of actin cytoskeletal dynamics in lymphocytes. Structure (2006) 1.43
Comparative structural analysis of the Erbin PDZ domain and the first PDZ domain of ZO-1. Insights into determinants of PDZ domain specificity. J Biol Chem (2006) 1.43
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. Cancer Res (2004) 1.38
In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis (2003) 1.37
Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol (2003) 1.37
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett (2005) 1.34
Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3. Protein Sci (2007) 1.31
Bivalent antibody phage display mimics natural immunoglobulin. J Immunol Methods (2004) 1.30
Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res (2010) 1.29
Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell (2011) 1.29
A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol (2008) 1.27
Crystal structure of procaspase-1 zymogen domain reveals insight into inflammatory caspase autoactivation. J Biol Chem (2008) 1.26
Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem (2007) 1.26
EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res (2004) 1.25
Inhibition of epithelial ductal branching in the prostate by sonic hedgehog is indirectly mediated by stromal cells. J Biol Chem (2003) 1.25
Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure (2009) 1.24
A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J Exp Med (2007) 1.22
Residues of human cytomegalovirus DNA polymerase catalytic subunit UL54 that are necessary and sufficient for interaction with the accessory protein UL44. J Virol (2004) 1.22
Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem (2006) 1.21
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood (2009) 1.19
Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest Ophthalmol Vis Sci (2008) 1.19
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther (2006) 1.18
Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling. J Biol Chem (2004) 1.18
Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice. Physiol Genomics (2002) 1.16
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate (2004) 1.12
Basis for abnormal desquamation and permeability barrier dysfunction in RXLI. J Invest Dermatol (2004) 1.12
Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit. J Virol (2004) 1.12
In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol (2003) 1.11
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol (2012) 1.11
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood (2007) 1.11
Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A (2007) 1.10
Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn Reson Med (2010) 1.10
Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A (2012) 1.10
Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J Biol Chem (2009) 1.09
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood (2007) 1.09
Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. Dev Biol (2006) 1.09
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B. J Med Chem (2009) 1.09